-
Type of Immunotherapy
-
PD-1
- Transmembrane protein expressed on T cells, B cells, and natural killer (NK) cells
- It is an inhibitory molecule that binds to the programmed cell death ligand 1 (PD-L1)
- The PD-1:PD-L1/2 interaction directly inhibits apoptosis of the tumor cell, promotes peripheral T effector cell exhaustion, and promotes conversion of T effector cells to Treg cells
| Drug mechanism | Drug name |
|---|---|
| Anti-PD-1 | - Nivolumab - Pembrolizumab - Cemiplimab - Dostarlimab - Retifanlimab - Toripalimab - Tislelizumab |
| Anti-PD-L1 | - Atezolizumab - Avelumab - Durvalumab |
| Anti-CTLA-4 | - Ipilimumab - Tremelimumab |
| Anti-LAG-3/anti-PD-1 | - Relatlimab and nivolumab |